News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

News

Article

August 29, 2023

AstraZeneca Joins Legal Battle Against IRA

Lawsuit comes amid announcement of the first 10 drugs eligible for negotiated prices in 2026.

USA flag, dollars and inscription inflation reduction act. Image Credit: Adobe Stock Images/Vitalii Vodolazskyi

Image Credit: Adobe Stock Images/Vitalii Vodolazskyi

Claiming the Inflation Reduction Act’s (IRA) drug provisions to be unconstitutional, AstraZeneca has become the latest drugmaker to pursue legal action against the US government. As reported by BioPharma Dive, the drugmaker’s lawsuit claims Medicare is unlawfully implementing provisions of last year’s Inflation Reduction Act, which provides the agency with authority to negotiate prices of certain top-selling drugs.

Currently, drugmakers that refuse to cooperate with Medicare on a lower price are subject to a heavy tax that’s only avoidable if products are removed from the insurance program.

“The IRA forces manufacturers to engage in purported ‘negotiations’ but affords them no bargaining power, no meaningful opportunity to walk away, and no ability to protect their interests against a so-called ‘maximum fair price’ capped at an amount drastically below actual fair market value,” alleged the British drug manufacturer in its lawsuit.

Reference: AstraZeneca the latest pharma to challenge drug pricing law. BioPharma Dive. August 25, 2023. Accessed August 29, 2023. https://www.biopharmadive.com/news/astrazeneca-ira-lawsuit-drug-pricing/691869/

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Advertisement
CVS Caremark Hit With $290 Million Penalty in False Claims Act Ruling
August 28th 2025

CVS Caremark Hit With $290 Million Penalty in False Claims Act Ruling

Nicholas Saraceno, Editor
Lawsuits Likely as Federal Authorities Roll Back Longstanding Vaccine Guidelines
August 28th 2025

Lawsuits Likely as Federal Authorities Roll Back Longstanding Vaccine Guidelines

Don Tracy, Associate Editor
Trump Executive Order Launches Six-Month API Stockpile to Boost US Drug Supply Chain Resilience
August 28th 2025

Trump Executive Order Launches Six-Month API Stockpile to Boost US Drug Supply Chain Resilience

Nicholas Saraceno, Editor
FDA Unveils PreCheck to Strengthen Domestic Pharmaceutical Supply Chain
August 28th 2025

FDA Unveils PreCheck to Strengthen Domestic Pharmaceutical Supply Chain

Nicholas Saraceno, Editor
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech
August 28th 2025

GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech

Don Tracy, Associate Editor
Credit: WESTOCK | stock.adobe.com
August 28th 2025

Why Every Pharma Executive Should Be Watching the Regeneron Kickback Case

Thani Jambulingam, PhD
Related Content
Advertisement
CVS Caremark Hit With $290 Million Penalty in False Claims Act Ruling
August 28th 2025

CVS Caremark Hit With $290 Million Penalty in False Claims Act Ruling

Nicholas Saraceno, Editor
Lawsuits Likely as Federal Authorities Roll Back Longstanding Vaccine Guidelines
August 28th 2025

Lawsuits Likely as Federal Authorities Roll Back Longstanding Vaccine Guidelines

Don Tracy, Associate Editor
Trump Executive Order Launches Six-Month API Stockpile to Boost US Drug Supply Chain Resilience
August 28th 2025

Trump Executive Order Launches Six-Month API Stockpile to Boost US Drug Supply Chain Resilience

Nicholas Saraceno, Editor
FDA Unveils PreCheck to Strengthen Domestic Pharmaceutical Supply Chain
August 28th 2025

FDA Unveils PreCheck to Strengthen Domestic Pharmaceutical Supply Chain

Nicholas Saraceno, Editor
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech
August 28th 2025

GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech

Don Tracy, Associate Editor
Credit: WESTOCK | stock.adobe.com
August 28th 2025

Why Every Pharma Executive Should Be Watching the Regeneron Kickback Case

Thani Jambulingam, PhD
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.